Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions

Methodological and translational gaps remain, including limited transparency, scarce external validation, and lack of patient-reported or longitudinal predictors. None of the models have been implemented as online calculators or integrated into electronic decision-support systems, limiting real-world uptake. Addressing these gaps is essential for developing clinically meaningful prediction tools to support personalized treatment in MM.